[5-(3-methylphenyl)-1H-indol-2-yl]methanol | 711010-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: [5-(3-methylphenyl)-1H-indol-2-yl]methanol
• CAS: 711010-59-2
• 化学式: C₁₆H₁₅NO
• 分子量: 237.301
• InChiKey: CJDLXFCZAUXBBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  36
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [5-(3-methylphenyl)-1H-indol-2-yl]methanol 、 乙酰氯 以afforded the title compound as an oil (3.94 g)的产率得到[5-(3-methylphenyl)-1H-indol-2-yl]methyl acetate
  参考文献：
  名称：

  Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)

  摘要：

  提供了式(I)和(II)的化合物，其中：X是碱金属或碱性胺基基团；R1是烷基、环烷基、—CH2-环烷基、吡啶基、—CH2-吡啶基、苯基或苄基，这些基团的环可以选择性地被取代；R2是H、卤素、烷基、全氟烷基、烷氧基、环烷基、—CH2-环烷基、—NH2或—NO2；R3是苯基、苄基、苄氧基、吡啶基或—CH2-吡啶基，这些基团的环可以选择性地被取代；或其药学上可接受的盐或酯形式，以及使用这些化合物作为纤溶酶原激活抑制剂-1（PAI-1）的抑制剂和治疗深静脉血栓和冠心病等纤溶障碍症状以及肺纤维化的治疗组合物和方法。

  公开号：

  US07101903B2
• 作为产物：
  描述：

  2-羟甲基-5-溴-1H-吲哚 、 3-甲基苯硼酸 在 palladium diacetate 四丁基溴化铵 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 [5-(3-methylphenyl)-1H-indol-2-yl]methanol
  参考文献：
  名称：

  [EN] SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AND 3-OXOACETIC ACID SUBSTITUTED 2-HYDROXYMETHYLINDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
  [FR] DERIVES DIHYDROPYRANO INDOLE-3,4-DIONE SUBSTITUES SERVANT D'INHIBITEURS D'UN INHIBITEUR 1 D'ACTIVATEUR DU PLASMINOGENE (PAI-1)

  摘要：

  公开号：

  WO2004052893A3

文献信息

• Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
  申请人：Wyeth

  公开号：US07101903B2

  公开（公告）日：2006-09-05

  Compounds of formula (I) and II) are provided wherein: X is an alkali metal or a basic amine moiety; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl, the rings of these groups being optionally substituted; R2 is H, halogen, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R3 is phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, with the rings of these groups being optionally substituted; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.

  提供了式(I)和(II)的化合物，其中：X是碱金属或碱性胺基基团；R1是烷基、环烷基、—CH2-环烷基、吡啶基、—CH2-吡啶基、苯基或苄基，这些基团的环可以选择性地被取代；R2是H、卤素、烷基、全氟烷基、烷氧基、环烷基、—CH2-环烷基、—NH2或—NO2；R3是苯基、苄基、苄氧基、吡啶基或—CH2-吡啶基，这些基团的环可以选择性地被取代；或其药学上可接受的盐或酯形式，以及使用这些化合物作为纤溶酶原激活抑制剂-1（PAI-1）的抑制剂和治疗深静脉血栓和冠心病等纤溶障碍症状以及肺纤维化的治疗组合物和方法。
• SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
  申请人：Wyeth

  公开号：EP1569639A2

  公开（公告）日：2005-09-07
• US7101903B2
  申请人：——

  公开号：US7101903B2

  公开（公告）日：2006-09-05
• US7459478B2
  申请人：——

  公开号：US7459478B2

  公开（公告）日：2008-12-02
• [EN] SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)<br/>[FR] DERIVES DIHYDROPYRANO INDOLE-3,4-DIONE SUBSTITUES SERVANT D'INHIBITEURS D'UN INHIBITEUR 1 D'ACTIVATEUR DU PLASMINOGENE (PAI-1)
  申请人：WYETH CORP

  公开号：WO2004052893A2

  公开（公告）日：2004-06-24

  Compounds of formula (I) and (II) are provided wherein: X is an alkali metal or a basic amine moiety; R1 is alkyl, cycloalkyl, -CH2-cycloalkyl, pyridinyl, -CH2-pyridinyl, phenyl or benzyl, the rings of these groups being optionally substituted; R2 is H, halogen, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, -CH2-cycloalkyl, -NH2, or -NO2; R3 is phenyl, benzyl, benzyloxy, pyridinyl, or -CH2-pyridinyl, with the rings of these groups being optionally substituted; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.